Developed with US respiratory specialist firm Innoviva, the drug (known as Breo Ellipta in the US) is GSK’s follow up to its respiratory blockbuster Advair/Seretide, but won’t come close to ...
Last quarter alone Advair generated sales of £848 million ... Trelegy may well cannibalise sales of GSK's newer double therapy, Breo Ellipta, which is slowly gaining market share.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results